Based on these results, we can infer that co-treatment with Gyp helps avert cardiac dysfunction linked to PAH by boosting factors that reduce inflammation, combat oxidative stress, and mitigate apoptosis. This evidence concerns the gene GYPB and pulmonary arterial hypertension.